Dapagliflozin Use with Creatinine 244 µmol/L
Yes, dapagliflozin can be initiated in a patient with serum creatinine of 244 µmol/L (approximately 2.76 mg/dL), which corresponds to an estimated GFR of approximately 20-30 mL/min/1.73 m², based on current guideline recommendations. 1
eGFR Threshold for Initiation
The most recent ADA/KDIGO 2022 consensus guidelines recommend initiating SGLT2 inhibitors, including dapagliflozin, in patients with type 2 diabetes and chronic kidney disease when eGFR ≥20 mL/min/1.73 m² 1. This represents a significant change from previous thresholds (≥25 or ≥30 mL/min/1.73 m²), driven by evidence from the DAPA-CKD trial which demonstrated clear efficacy and safety for dapagliflozin in patients with eGFR ≥25 mL/min/1.73 m² 1, 2.
Converting Your Patient's Creatinine
A serum creatinine of 244 µmol/L equals approximately 2.76 mg/dL. Depending on the patient's age, sex, and race, this typically corresponds to an eGFR in the range of 20-30 mL/min/1.73 m² (CKD stage 4). You must calculate the actual eGFR using the CKD-EPI equation before making the final decision.
Clinical Decision Algorithm
If eGFR ≥25 mL/min/1.73 m²:
- Initiate dapagliflozin 10 mg daily - strongest evidence from DAPA-CKD trial 1, 2
- Particularly beneficial if patient has albuminuria (UACR ≥200 mg/g) or heart failure 1
If eGFR 20-24 mL/min/1.73 m²:
- Can initiate dapagliflozin 10 mg daily 1
- Evidence strongest for patients with concomitant albuminuria or heart failure
- FDA labeling states "initiation not recommended with eGFR <25 mL/min/1.73 m²" but allows continuation 1
- However, guideline recommendations supersede FDA labeling in this case, as KDIGO/ADA explicitly recommend initiation at eGFR ≥20 1
If eGFR <20 mL/min/1.73 m²:
- Do not initiate - insufficient evidence 1
Critical Renal Outcomes Evidence
The DAPA-CKD trial enrolled 4,304 patients with CKD (eGFR 25-75 mL/min/1.73 m² and albuminuria 200-5,000 mg/g) and demonstrated that dapagliflozin reduced the composite primary outcome of ≥50% sustained eGFR decline, end-stage kidney disease, or renal/cardiovascular death by 39% (HR 0.61,95% CI 0.51-0.72) 2. Importantly, these benefits occurred regardless of diabetes status 2.
Subgroup analyses from CREDENCE and DAPA-CKD trials in patients with baseline eGFR <30 mL/min/1.73 m² showed consistent efficacy and safety 1. Additionally, dapagliflozin actually reduced the risk of abrupt kidney function declines (HR 0.68) and did not increase acute kidney injury events 3.
Expected Initial Renal Changes
Expect a small, reversible decline in eGFR within the first 1-2 weeks after starting dapagliflozin 1. This hemodynamic effect:
- Typically stabilizes by week 2
- Does not require drug discontinuation 1
- Represents beneficial intraglomerular pressure reduction, not kidney injury
- Is followed by long-term renal protection 2
In one study of patients with moderate renal impairment, mean serum creatinine increased by +0.18 mg/dL at 1 week with dapagliflozin 10 mg but did not change further through 104 weeks 4.
Continuation Below Initiation Threshold
Once initiated, continue dapagliflozin even if eGFR falls below 20 mL/min/1.73 m² unless the patient is not tolerating treatment or kidney replacement therapy is initiated 1. Both CREDENCE and DAPA-CKD trial protocols specified continuation when eGFR fell below initiation thresholds, demonstrating ongoing benefit 1.
Essential Monitoring and Risk Mitigation
Before Initiation:
- Calculate eGFR using CKD-EPI equation
- Assess volume status, especially if patient is elderly or on loop diuretics 1, 5
- Consider proactive diuretic dose reduction if high risk for volume depletion 1
- Check baseline electrolytes
After Initiation:
- Recheck creatinine/eGFR at 1-2 weeks to document expected initial dip 1
- Monitor for signs of hypovolemia (dizziness, orthostasis) 1, 5
- If creatinine changes don't follow the expected pattern (small initial increase then stabilization), evaluate for acute kidney injury 5
Ongoing:
- Monitor eGFR with increasing frequency as kidney function declines 1
- Institute sick day protocol: hold dapagliflozin during acute illness to prevent volume depletion and ketoacidosis 1, 5
Important Caveats
Glycemic Efficacy is Reduced:
At this level of renal function, dapagliflozin will have minimal glucose-lowering effect 1, 6, 4. One study showed that in patients with moderate renal impairment, dapagliflozin did not improve glycemic control (HbA1c reduction similar to placebo) 4. However, the cardiovascular and renal protective benefits remain intact 1, 2.
Adjust Insulin/Sulfonylureas:
If the patient is on insulin or sulfonylureas, consider dose reduction to minimize hypoglycemia risk, though absolute risk is low at reduced eGFR 1.
Ketoacidosis Risk:
Educate about diabetic ketoacidosis signs/symptoms 1, 5. Maintain at least low-dose insulin in insulin-requiring patients 1. Hold during illness, surgery, or prolonged fasting 5.
Genital Infections:
Counsel on genital hygiene; genital mycotic infections occur in approximately 5% of patients 1, 5.
Why This Matters for Mortality and Morbidity
In the DAPA-CKD trial, all-cause mortality was reduced by 31% (HR 0.69,95% CI 0.53-0.88) with dapagliflozin 2. The composite of cardiovascular death or heart failure hospitalization was reduced by 29% (HR 0.71) 2. These are the outcomes that matter most—not just glucose control—and they persist even at advanced CKD stages.
The 2025 ADA Standards of Care emphasize that SGLT2 inhibitors reduce heart failure hospitalization by 27-39% across multiple trials 7, making them essential therapy for patients with diabetes and reduced kidney function who are at extremely high cardiovascular risk.